Elotuzumab MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Distribution ChannelBy Combination RegimenBy Treatment Line

Elotuzumab is a monoclonal antibody that targets the SLAMF7 protein on myeloma and natural killer cells, administered by intravenous infusion in combination with other anti-myeloma agents rather than as a standalone therapy. It is used to treat adult patients with relapsed or refractory multiple myeloma who have already received one or more prior lines of treatment. Purchasers are hospital and specialty oncology pharmacies that supply infusion centers, clinics and drug treatment centers where oncologists administer the combination regimen.

The global elotuzumab market is valued at USD 1.27 billion in 2025 and is set to reach USD 2.69 billion by 2034, a compound annual growth rate of 8.7% across the 2026-2034 forecast period. The study tracks the market across USD 0.64 billion in 2020, USD 1.2 billion in 2024, USD 1.38 billion in 2026 and USD 1.927 billion in 2030.

Composition changes more than the total does. 400mg Injection, at 9.36%, outgrows 300mg Injection at 7.78%, and its share moves from 56.77% to 60%. 400mg Injection stays the largest line throughout, at USD 0.721 billion in 2025 and USD 1.614 billion in 2034. 400mg Injection take share over the period; 300mg Injection give it up while still growing in absolute terms.

Cut by application, the largest line is Hospital: 61.97% of 2025 revenue, worth USD 0.787 billion, and 57.99% at USD 1.56 billion by 2034. Clinic grows faster at 10.12% against 7.9%, moving from 24.02% of revenue to 26.99% by 2034. Both this axis and the type one divide the same revenue, which is why they are alternative views, not components.

Geographically, 51.97% of 2025 revenue sits in North America (USD 0.66 billion rising to USD 1.264 billion) ahead of Europe at 27.01% and USD 0.343 billion. Middle East and Africa is smallest, at 2.52%. Asia Pacific, Latin America and Middle East and Africa gain share across the period, so growth is not distributed evenly between regions.

Behind these figures sit five regions, two type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.

• A forecast-period rate of 8.7% takes the market from USD 1.27 billion in 2025 to USD 2.69 billion in 2034, against 14.69% recorded over the 2020-2025 historical period.
• The largest line by type is 400mg Injection, worth USD 0.721 billion and 56.77% of revenue in 2025, rising to USD 1.614 billion and 60% by 2034.
• Scenario range for 2034 runs from USD 2.367 billion in the bear case to USD 3.013 billion in the bull case, against a base-case USD 2.69 billion, the spread a plan built on this forecast has to absorb.
• The largest region is North America, generating USD 0.66 billion in 2025 (51.97% of the global total) and USD 1.264 billion by 2034, ahead of Europe at 27.01%.
• The United States accounts for 91.97% of North America in the base year, worth USD 0.607 billion in 2025 and reaching USD 1.163 billion by 2034, the worked country example carried through that region's chapters.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 8.7% compounding underneath both.

All three are changes in mix, not in direction: nothing contracts, and the movement is in which lines and regions absorb the new revenue.

400mg Injection grows faster than 300mg Injection. 9.36% against 7.78%: that gap, between 400mg Injection and 300mg Injection, is the largest on the type axis. By 2034 the two sit at 60% and 40% of revenue, against 56.77% and 43.23% in 2025. Revenue rises on both sides; USD 0.721 billion to USD 1.614 billion and USD 0.549 billion to USD 1.076 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 15.04% of revenue in 2025 to 20% in 2034, worth USD 0.191 billion rising to USD 0.538 billion; Latin America moves from 3.46% of revenue in 2025 to 4.01% in 2034, worth USD 0.044 billion rising to USD 0.108 billion; Middle East and Africa moves from 2.52% of revenue in 2025 to 3.01% in 2034, worth USD 0.032 billion rising to USD 0.081 billion. Against that, North America at 51.97% moving to 47%, Europe at 27.01% moving to 25.99%, a fall in share, not in revenue. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

Fifteen years without a discontinuity. Fifteen years of revenue run USD 0.64 billion in 2020, USD 1.2 billion in 2024, USD 1.27 billion in 2025, USD 1.38 billion in 2026, USD 1.927 billion in 2030 and USD 2.69 billion in 2034. Against 14.69% through the historical period, the 8.7% forecast rate is a continuation; no year in the series interrupts it. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the type and regional axes, not by the headline rate.

400mg Injection adds the most incremental growth

Three sources account for the growth to 2034: 8.7% compounding across the base, share moving toward the faster type lines, and above-market expansion in the leading regions.

What holds the forecast back

Upside case: USD 3.013 billion by 2034

Revenue is concentrated in 400mg Injection

In North America, 51.97% of global revenue puts 2025 at USD 0.66 billion and reaches USD 1.264 billion by 2034. It is a dominant region on this axis, first by revenue throughout the period.

By 2034 the share stands at 47%, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

400mg Injection leads here as it does globally, at 56.77% of 2025 revenue, and 400mg Injection again grows fastest at 9.36%. The full report breaks North America out along every axis and by country.

The United States is the largest market within North America, generating USD 0.607 billion in 2025 and projected to reach USD 1.163 billion by 2034. 91.97% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Set against USD 0.66 billion and USD 1.264 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is 400mg Injection at 56.77% of 2025 revenue, easing to 60% by 2034, and the fastest is 400mg Injection at 9.36%, from 56.77% to 60%. With 91.97% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The United States carries its own type breakdown in the full report.

Elotuzumab is regulated as a biologic in the United States, falling under the Food and Drug Administration's oversight of monoclonal antibody therapeutics. A supplier must secure approval through the Center for Drug Evaluation and Research's biologics licensing pathway, supported by clinical evidence of safety and efficacy in the intended oncology indication. Manufacturing facilities are subject to current Good Manufacturing Practice inspection, covering potency, purity, and sterility of the infusion product. Labelling must carry the approved prescribing information, including boxed warnings where applicable, dosing guidance, and risk information for infusion reactions. Post-marketing pharmacovigilance obligations continue after approval, requiring the holder to report adverse events and update the label as new safety data emerges. Distribution through specialty pharmacy channels is typical given the product's storage and administration requirements.

Bristol Myers Squibb and Abbvie are the suppliers covered in the United States. 400mg Injection is where the volume is, at 56.77% of 2025 revenue, and it is growing fastest as well at 9.36%. The full report covers country-level positioning and shares company by company; this summary does not.

Canada is sized at USD 0.053 billion in 2025, rising to USD 0.101 billion by 2034; 4.17% of global revenue and 8.03% of North America. It is reported separately from the United States across every segmentation axis in the full report.

In Europe, 27.01% of global revenue puts 2025 at USD 0.343 billion rising to USD 0.699 billion in 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share stands at 25.99%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Within the region the type split tracks the global one; 56.77% of 2025 revenue in 400mg Injection, fastest growth of 9.36% in 400mg Injection. The full report breaks Europe out along every axis and by country.

30.03% of Europe's base-year revenue comes from Germany; USD 0.103 billion, rising to USD 0.21 billion by 2034. Its 30.03% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Against regional totals of USD 0.343 billion in 2025 and USD 0.699 billion in 2034, it is the country the full report breaks out in detail.

Composition here matches the global split: the largest line is 400mg Injection at 56.77% of 2025 revenue, easing to 60% by 2034, and the fastest is 400mg Injection at 9.36%, from 56.77% to 60%. Since 30.03% of Europe's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Germany carries its own type breakdown in the full report.

As an European Union member state, Germany regulates elotuzumab under the centralised procedure administered by the European Medicines Agency, since monoclonal antibodies for oncology indications fall within the mandatory scope of that route. A marketing authorisation granted at the EU level applies directly, and the German Federal Institute for Drugs and Medical Devices participates in the scientific assessment alongside other member state authorities. Once authorised, pricing and reimbursement decisions proceed through Germany's early benefit assessment conducted by the Federal Joint Committee, with support from the Institute for Quality and Efficiency in Health Care. Labelling must conform to the EU's harmonised summary of product characteristics and package leaflet requirements, presented in German. Good Manufacturing Practice compliance and batch release testing within the European Economic Area are required before the product reaches hospital pharmacies and infusion centres.

Competition in Germany runs between the suppliers this study tracks: Bristol Myers Squibb and Abbvie. Volume and growth sit in the same line, 400mg Injection, at 56.77% of 2025 revenue and 9.36% growth. That makes Europe a 27.01% share of 2025 global revenue, USD 0.343 billion rising to USD 0.699 billion, for any supplier deciding where to concentrate.

Within Europe, France accounts for 18.95% of regional revenue and 5.12% of the global total, worth USD 0.065 billion in 2025 and USD 0.133 billion by 2034.

Within Europe, the United Kingdom accounts for 16.91% of regional revenue and 4.57% of the global total, worth USD 0.058 billion in 2025 and USD 0.119 billion by 2034.

USD 0.191 billion of 2025 revenue is generated in Asia Pacific, 15.04% of the global elotuzumab market and reaches USD 0.538 billion by 2034. Among the five regions it ranks third by revenue in both years.

Its share rises to 20% over the forecast period, at a pace above the 8.7% global rate, so this region warrants separate treatment and should not be scaled off the total.

400mg Injection leads here as it does globally, at 56.77% of 2025 revenue, and 400mg Injection again grows fastest at 9.36%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

The largest single market in Asia Pacific is Japan, at USD 0.076 billion in 2025 and USD 0.183 billion in 2034. Its 39.79% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Against regional totals of USD 0.191 billion in 2025 and USD 0.538 billion in 2034, it is the country the full report breaks out in detail.

Composition here matches the global split: the largest line is 400mg Injection at 56.77% of 2025 revenue, easing to 60% by 2034, and the fastest is 400mg Injection at 9.36%, from 56.77% to 60%. With 39.79% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-type revenue for Japan appears on its own in the full report.

Japan's Pharmaceuticals and Medical Devices Agency reviews elotuzumab under the biologics approval framework established by the Pharmaceuticals and Medical Devices Act, with the Ministry of Health, Labour and Welfare granting final marketing authorisation. Because the product originates from clinical development conducted primarily outside Japan, the review typically considers bridging data to confirm that efficacy and safety findings extrapolate to the Japanese patient population. Approved labelling must be rendered in Japanese and aligned with the agency's package insert format, specifying indication, dosing, and precautions for infusion-related reactions. Manufacturing and quality control must satisfy Japan's own Good Manufacturing Practice standards, verified through facility inspection. Once approved, the product is generally evaluated for inclusion on the National Health Insurance price list, a separate administrative step from the marketing approval itself, governing eventual hospital reimbursement.

The suppliers tracked in this study (Bristol Myers Squibb and Abbvie) compete in Japan across the type lines above. 400mg Injection is where the volume is, at 56.77% of 2025 revenue, and it is growing fastest as well at 9.36%. A supplier weighted toward Asia Pacific is competing over a base of USD 0.191 billion in 2025 reaching USD 0.538 billion by 2034, 15.04% of global revenue at the start of that period.

Within Asia Pacific, China accounts for 29.84% of regional revenue and 4.49% of the global total, worth USD 0.057 billion in 2025 and USD 0.194 billion by 2034.

Within Asia Pacific, India accounts for 12.04% of regional revenue and 1.81% of the global total, worth USD 0.023 billion in 2025 and USD 0.075 billion by 2034.

3.46% of the global elotuzumab market sits in Latin America in 2025, worth USD 0.044 billion on the way to USD 0.108 billion by 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

4.01% of global revenue sits here by 2034, up from the 2025 level, at a pace above the 8.7% global rate, so this region warrants separate treatment and should not be scaled off the total.

The type mix reported at global level applies here, with 400mg Injection the largest line at 56.77% of 2025 revenue and 400mg Injection the fastest-growing at 9.36%. Per-axis and per-country detail for Latin America sits in the full report.

The largest single market in Latin America is Brazil, at USD 0.024 billion in 2025 and USD 0.059 billion in 2034. It accounts for 54.55% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 0.044 billion and USD 0.108 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is 400mg Injection at 56.77% of 2025 revenue, easing to 60% by 2034, and the fastest is 400mg Injection at 9.36%, from 56.77% to 60%. Its 54.55% weight in Latin America means those movements carry straight into the regional totals. The full report reports Brazil by type separately.

Brazil's National Health Surveillance Agency, ANVISA, classifies elotuzumab as a biological product requiring registration before it may be marketed, following a dossier review that examines manufacturing consistency, clinical safety, and efficacy data. Given the complexity of biologic manufacturing, ANVISA applies its specific biological product registration pathway rather than the generic pharmaceutical route, with attention to comparability of the manufacturing process across batches. Labelling must be presented in Portuguese and conform to ANVISA's package insert and patient information requirements, including storage and handling instructions appropriate to a cold-chain infusion product. Manufacturing sites, whether domestic or foreign, must demonstrate Good Manufacturing Practice compliance recognised by ANVISA, often verified through inspection or reliance on prior international certification. Import and distribution require an ANVISA-issued operating authorisation held by the local importer or distributor.

The suppliers tracked in this study (Bristol Myers Squibb and Abbvie) compete in Brazil across the type lines above. 400mg Injection is where the volume is, at 56.77% of 2025 revenue, and it is growing fastest as well at 9.36%. A supplier weighted toward Latin America is competing over a base of USD 0.044 billion in 2025 reaching USD 0.108 billion by 2034, 3.46% of global revenue at the start of that period.

Within Latin America, Mexico accounts for 29.55% of regional revenue and 1.02% of the global total, worth USD 0.013 billion in 2025 and USD 0.032 billion by 2034.

In Middle East and Africa, 2.52% of global revenue puts 2025 at USD 0.032 billion with USD 0.081 billion projected for 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

By 2034 the share has moved up to 3.01%, because it outgrows the market's 8.7%; the revenue added here is disproportionate to where the region started.

The type mix reported at global level applies here, with 400mg Injection the largest line at 56.77% of 2025 revenue and 400mg Injection the fastest-growing at 9.36%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.013 billion in 2025 and USD 0.032 billion in 2034. Its 40.63% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. Against regional totals of USD 0.032 billion in 2025 and USD 0.081 billion in 2034, it is the country the full report breaks out in detail.

The type pattern in Saudi Arabia is the global one: 56.77% of 2025 revenue in 400mg Injection, 60% by 2034, against 9.36% growth in 400mg Injection taking it from 56.77% to 60%. Since 40.63% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-type revenue for Saudi Arabia appears on its own in the full report.

The Saudi Food and Drug Authority governs the registration and marketing of elotuzumab within the Kingdom, treating it as a biological therapeutic subject to its dedicated biologics evaluation pathway. Registration generally draws on prior approval and clinical data from a recognised reference regulatory authority, supplemented by local review of labelling and risk management documentation suited to the Saudi healthcare setting. Approved products must carry labelling in Arabic alongside English, including dosing, storage, and infusion-related safety information consistent with the authority's pharmacovigilance requirements. Manufacturing facilities must meet Good Manufacturing Practice standards recognised by the authority, and imported consignments are subject to batch testing or certificate verification before release into the local market. Hospital procurement and reimbursement decisions, including listing on relevant formularies, are handled separately from the marketing authorisation itself.

Competition in Saudi Arabia runs between the suppliers this study tracks: Bristol Myers Squibb and Abbvie. 400mg Injection is both the largest line, at 56.77% of 2025 revenue, and the fastest-growing at 9.36%. That makes Middle East and Africa a 2.52% share of 2025 global revenue, USD 0.032 billion rising to USD 0.081 billion, for any supplier deciding where to concentrate.

Within Middle East and Africa, South Africa accounts for 25% of regional revenue and 0.63% of the global total, worth USD 0.008 billion in 2025 and USD 0.02 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Application, Distribution Channel, Combination Regimen, Treatment Line, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.